Literature DB >> 17109308

Pharmacokinetic interactions between buprenorphine and antiretroviral medications.

R Douglas Bruce1, Elinore McCance-Katz, Evan D Kharasch, David E Moody, Gene D Morse.   

Abstract

Buprenorphine is used for the treatment of opioid dependence. As the number of persons receiving buprenorphine treatment and antiretroviral therapy continues to grow, so too does the existence and clinical impact of drug interactions between buprenorphine and medications for treating human immunodeficiency virus (HIV) infection. Awareness that such interactions exist may deter some patients and physicians from initiating potentially lifesaving therapy or lead to complications among patients whose treatment is already under way. Complications include nonadherence to antiretroviral therapy and the development of viral resistance. Illicit drug use is a frequent consequence of adverse drug effects experienced by injection drug users. The occurrence of unrecognized drug interactions can lead to unsuccessful therapy for HIV infection and the treatment of substance dependence. The present review is organized to provide a working background of buprenorphine pharmacology. Review of the current state of knowledge regarding specific interactions between buprenorphine and antiretrovirals is followed by a review of the clinical applicability of these interactions.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17109308     DOI: 10.1086/508186

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  22 in total

1.  Gender differences in pharmacokinetics of maintenance dosed buprenorphine.

Authors:  David E Moody; Wenfang B Fang; Jerdravee Morrison; Elinore McCance-Katz
Journal:  Drug Alcohol Depend       Date:  2011-04-23       Impact factor: 4.492

2.  Nanoformulated antiretroviral drug combinations extend drug release and antiretroviral responses in HIV-1-infected macrophages: implications for neuroAIDS therapeutics.

Authors:  Ari S Nowacek; JoEllyn McMillan; Reagan Miller; Alec Anderson; Barrett Rabinow; Howard E Gendelman
Journal:  J Neuroimmune Pharmacol       Date:  2010-03-17       Impact factor: 4.147

3.  Infectious disease comorbidities adversely affecting substance users with HIV: hepatitis C and tuberculosis.

Authors:  Gerald Friedland
Journal:  J Acquir Immune Defic Syndr       Date:  2010-12       Impact factor: 3.731

Review 4.  Pharmacogenomics of CYP3A: considerations for HIV treatment.

Authors:  Sukhwinder S Lakhman; Qing Ma; Gene D Morse
Journal:  Pharmacogenomics       Date:  2009-08       Impact factor: 2.533

5.  Pharmacokinetic interactions between buprenorphine/naloxone and once-daily lopinavir/ritonavir.

Authors:  Robert Douglas Bruce; Frederick L Altice; David E Moody; Gene D Morse; Laurie Andrews; Shen-Nan Lin; Wenfang B Fang; Qing Ma; Gerald H Friedland
Journal:  J Acquir Immune Defic Syndr       Date:  2010-08       Impact factor: 3.731

6.  Buprenorphine metabolites, buprenorphine-3-glucuronide and norbuprenorphine-3-glucuronide, are biologically active.

Authors:  Sarah M Brown; Michael Holtzman; Thomas Kim; Evan D Kharasch
Journal:  Anesthesiology       Date:  2011-12       Impact factor: 7.892

Review 7.  HIV infection and risk of overdose: a systematic review and meta-analysis.

Authors:  Traci C Green; Samuel K McGowan; Michael A Yokell; Enrique R Pouget; Josiah D Rich
Journal:  AIDS       Date:  2012-02-20       Impact factor: 4.177

8.  High-sensitivity analysis of buprenorphine, norbuprenorphine, buprenorphine glucuronide, and norbuprenorphine glucuronide in plasma and urine by liquid chromatography-mass spectrometry.

Authors:  Karen J Regina; Evan D Kharasch
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2013-09-08       Impact factor: 3.205

9.  NanoART synthesis, characterization, uptake, release and toxicology for human monocyte-macrophage drug delivery.

Authors:  Ari S Nowacek; Reagan L Miller; Joellyn McMillan; Georgette Kanmogne; Michel Kanmogne; R Lee Mosley; Zhiya Ma; Sabine Graham; Mahesh Chaubal; Jane Werling; Barrett Rabinow; Huanyu Dou; Howard E Gendelman
Journal:  Nanomedicine (Lond)       Date:  2009-12       Impact factor: 5.307

Review 10.  Efavirenz: a decade of clinical experience in the treatment of HIV.

Authors:  Franco Maggiolo
Journal:  J Antimicrob Chemother       Date:  2009-09-18       Impact factor: 5.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.